While results from clinical trials are important in determining the efficacy of treatment, restrictive eligibility criteria may limit generalizability to patient populations in the real-world setting. Real-world analyses can therefore identify subgroups of patients who may respond differently to specific therapeutic regimens. This supplementary data is supportive to the research article entitled “Real-world outcomes of immunotherapy–based regimens in first-line advanced non-small cell lung cancer” . Using electronic health records data from a large demographically and geographically diverse oncology database, we present real-world progression-free survival (rwPFS) outcomes for patients with advanced non-small cell lung cancer in the United States treated with either first-line immunotherapy as monotherapy or single-agent immunotherapy combined with chemotherapy. rwPFS was estimated for patients in each treatment group using Kaplan-Meier methods; analyses were conducted separately for patients with squamous and non-squamous histology and stratified by Eastern Cooperative Oncology Group performance status, tumor programmed death ligand-1 expression, and presence of brain metastases.
Bibliographical noteFunding Information:
Medical writing and editorial support were provided by Stefanie Puglielli, PhD, CMPP, and Brooke Middlebrook, CMPP, Evidence Medical Affairs (Philadelphia, PA, USA) and was funded by Bristol Myers Squibb.
- Immune checkpoint inhibitors
- Non-small cell lung cancer
- Real-world outcomes
PubMed: MeSH publication types
- Journal Article